Profil
David Moskowitz currently works at hC Bioscience, Inc., as Independent Board Director.
Aktive Positionen von David Moskowitz
Unternehmen | Position | Beginn |
---|---|---|
Hc Bioscience, Inc.
Hc Bioscience, Inc. Pharmaceuticals: MajorHealth Technology hC Bioscience, Inc. is a biotech company based in Cambridge, MA and has subsidiaries in the United States. A single trna therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. hC Bioscience is dedicated to improving the lives of patients by developing first-in-class trna-based therapeutics that target protein dysfunction. The company's innovative approach to precision protein editing has the potential to treat genetically defined conditions that account for 10-15% of all human diseases. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). The company was founded in 2021 by Leslie J. Williams, who has been the CEO since then. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Hc Bioscience, Inc.
Hc Bioscience, Inc. Pharmaceuticals: MajorHealth Technology hC Bioscience, Inc. is a biotech company based in Cambridge, MA and has subsidiaries in the United States. A single trna therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. hC Bioscience is dedicated to improving the lives of patients by developing first-in-class trna-based therapeutics that target protein dysfunction. The company's innovative approach to precision protein editing has the potential to treat genetically defined conditions that account for 10-15% of all human diseases. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). The company was founded in 2021 by Leslie J. Williams, who has been the CEO since then. | Health Technology |